Tax Management India. Com
Law and Practice  :  Digital eBook
Research is most exciting & rewarding
  TMI - Tax Management India. Com
Follow us:
  Facebook   Twitter   Linkedin   Telegram

Home Case Index All Cases Central Excise Central Excise + AT Central Excise - 2022 (7) TMI AT This

  • Login
  • Cases Cited
  • Referred In
  • Summary

Forgot password       New User/ Regiser

⇒ Register to get Live Demo



 

2022 (7) TMI 351 - AT - Central Excise


Issues Involved:
1. Valuation of medicaments supplied to institutional buyers without retail sale.
2. Applicability of MRP-based assessment under Section 4A of the Central Excise Act, 1944.
3. Consistency with previous tribunal decisions and res judicata.

Issue-wise Detailed Analysis:

1. Valuation of Medicaments Supplied to Institutional Buyers Without Retail Sale:
The core issue revolves around whether medicaments supplied by the appellant to institutional buyers like Indian Railways, ESI, BHEL, and SAIL, which are marked "Not for sale/Hospital supply not for sale," should be assessed based on the Maximum Retail Price (MRP). The institutional buyers use these medicaments in their hospitals either free of cost or at a nominal charge, and there is no retail sale involved.

2. Applicability of MRP-based Assessment Under Section 4A of the Central Excise Act, 1944:
The Revenue contended that the appellant was required to affix MRP on these goods and assess them on an MRP basis under Section 4A of the Central Excise Act, 1944. The Adjudicating Authority confirmed the demand, which was upheld by the Commissioner (Appeals). However, the appellant argued that the issue was already settled in their favor in previous tribunal decisions, specifically in the tribunal's final order dated 28.06.2019 (2019 (10) TMI 810 CESTAT AHMEDABAD), which was accepted by the department without further appeal. The tribunal in the previous case had held that supplies intended for consumption by institutional buyers in their hospitals and not intended for retail sale are not liable to be assessed under Section 4A.

3. Consistency with Previous Tribunal Decisions and Res Judicata:
The tribunal noted that the issue had already been decided in the appellant's favor for earlier periods, and the department had accepted those decisions without further appeal. The tribunal cited its previous order dated 28.06.2019, which set aside the demand for the periods January 2005 to May 2013 and March 2010 to February 2013, and the Additional Commissioner's order dated 30.01.2020, which set aside the demand for subsequent periods. The tribunal emphasized that the facts of the present case were identical except for the period involved, making the issue res judicata.

Conclusion:
The tribunal concluded that since the issue had already been settled in favor of the appellant in previous identical cases and accepted by the department, the present demands were not sustainable. The tribunal set aside the impugned orders and allowed the appeals, reinforcing that medicaments supplied to institutional buyers for use in their hospitals, marked "Not for sale/Hospital supply not for sale," are not subject to MRP-based assessment under Section 4A of the Central Excise Act, 1944.

Final Order:
The tribunal pronounced the decision in the open court on 07.07.2022, setting aside the impugned orders and allowing the appeals.

 

 

 

 

Quick Updates:Latest Updates